EUVIMEDEUVIMED entdecken
Übersichtsarbeit

New therapeutic approaches against pulmonary fibrosis

Dongke Yu, Yu Xiang, Tingting Gou, Rongsheng Tong, Chuan Xu, Lu Chen, Ling Zhong, Jianyou Shi

Bioorganic Chemistry · 2023-09 · 138 · 106592

DOI: 10.1016/j.bioorg.2023.106592 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2023-09. Verfasst von Dongke Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Scie…. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, COVID-19. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 203 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary fibrosis is the end-stage change of a large class of lung diseases characterized by the proliferation of fibroblasts and the accumulation of a large amount of extracellular matrix, accompanied by inflammatory damage and tissue structure destruction, which also shows the normal alveolar tissue is damaged and then abnormally repaired resulting in structural abnormalities (scarring). Pulmonary fibrosis has a serious impact on the respiratory function of the human body, and the clinical manifestation is progressive dyspnea. The incidence of pulmonary fibrosis-related diseases is increasing year by year, and no curative drugs have appeared so far. Nevertheless, research on pulmonary fibrosis have also increased in recent years, but there are no breakthrough results. Pathological changes of pulmonary fibrosis appear in the lungs of patients with coronavirus disease 2019 (COVID-19) that have not yet ended, and whether to improve the condition of patients with COVID-19 by means of the anti-fibrosis therapy, which are the questions we need to address now. This review systematically sheds light on the current state of research on fibrosis from multiple perspectives, hoping to provide some references for design and optimization of subsequent drugs and the selection of anti-fibrosis treatment plans and strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary FibrosisCOVID-19HumansLungFibrosisFibroblasts

Stichwörter der Autor:innen

COVID-19CompoundIPFPulmonary fibrosisTarget

Autor:innen und Institutionen

  • Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China; Personalized Drug…
  • College of Medicine, University of Electronic Science and Technology, Chengdu 610072, China.
  • State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacology, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
  • Department of Oncology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China.
  • Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology, C…

Zitieren

APA

Yu, D., Xiang, Y., Gou, T., Tong, R., Xu, C., Chen, L., Zhong, L., & Shi, J. (2023). New therapeutic approaches against pulmonary fibrosis. Bioorganic Chemistry, 138, 106592. https://doi.org/10.1016/j.bioorg.2023.106592

Vancouver

Yu D, Xiang Y, Gou T, Tong R, Xu C, Chen L, et al. New therapeutic approaches against pulmonary fibrosis. Bioorganic Chemistry. 2023;138:106592. doi:10.1016/j.bioorg.2023.106592

BibTeX
@article{Yu2023,
  author = {Yu, Dongke and Xiang, Yu and Gou, Tingting and Tong, Rongsheng and Xu, Chuan and Chen, Lu and Zhong, Ling and Shi, Jianyou},
  title = {New therapeutic approaches against pulmonary fibrosis},
  journal = {Bioorganic Chemistry},
  year = {2023},
  volume = {138},
  pages = {106592},
  doi = {10.1016/j.bioorg.2023.106592}
}
Kostenlos starten →